State Street’s TetraLogic Pharmaceuticals Corporation TLOG Stock Holding History

State Street’s Portfolio TLOG Stock Details TLOG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q2	–	Sell	-22,700	Closed	-$145K	–	3702
2014 Q1	$145K	Buy	+22,700	New	+$205K	﹤0.01%	3487

Other funds holding TLOG

Clarus Ventures Cambridge, Massachusetts $425M AUM 26.13% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

PRCM

Pine River Capital Management Minnetonka, Minnesota $32.9M AUM 4.47% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

FWC

First Washington Corp Seattle, Washington $353M AUM 41.46% 1-Year Est. Return

Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

State Street's TLOG Position: Q2 2014 in Review

State Street sold out of TetraLogic Pharmaceuticals Corporation (TLOG) in Q2 2014, closing a stake of 22,700 shares — an estimated $145K sold.

State Street first reported a position in TLOG in Q1 2014 and held it in 1 quarter. The position peaked at $145K in Q1 2014. 28 funds tracked by Wall St. Rank hold TLOG as of Q2 2014.

State Street reported no remaining TetraLogic Pharmaceuticals Corporation position as of Q2 2014 after selling out during the quarter.
State Street sold 22,700 TetraLogic Pharmaceuticals Corporation shares in Q2 2014, an estimated $145K.
State Street first reported a position in TetraLogic Pharmaceuticals Corporation in Q1 2014 and held it in 1 quarter.
State Street's TetraLogic Pharmaceuticals Corporation position peaked at $145K in Q1 2014.
28 funds tracked by Wall St. Rank held TetraLogic Pharmaceuticals Corporation as of Q2 2014.

Based on State Street's 13F filing for Q2 2014, filed 12 Aug 2014.